Trend of HPV 16/18 Genotypes in Cervical Intraepithelial Neoplasia Grade 3: Data for 2007–2018

References

• SerranoB, AlemanyL, TousS, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38. doi:10.1186/1750-9378-7-3823273245
   PubMed Web of Science ®Google Scholar
• LiveraniCA, Di GiuseppeJ, GiannellaL, Delli CarpiniG, CiavattiniA. Cervical cancer screening guidelines in the postvaccination era: review of the literature. J Oncol. 2020;2020:8887672. doi:10.1155/2020/888767233204265
   PubMed Web of Science ®Google Scholar
• ArbynM, XuL. Efficacy and safety of prophylactic HPV vaccines. A cochrane review of randomized trials. Expert Rev Vaccines. 2018;17(12):1085–1091. doi:10.1080/14760584.2018.154828230495978
   PubMed Web of Science ®Google Scholar
• CiavattiniA, GiannellaL, De VincenzoR, et al. HPV vaccination: the position paper of the Italian society of colposcopy and cervico-vaginal pathology (SICPCV). Vaccines (Basel). 2020;8(3):E354. doi:10.3390/vaccines803035432630772
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. HPV vaccine information for clinicians-fact sheet. Available from:https://www.cdc.gov/std/HPV. Accessed 98, 2021.
   Google Scholar
• Paz-ZuluetaM, Álvarez-paredesL, Rodríguez DíazJC, et al. Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions. BMC Cancer. 2018;18(1):112. doi:10.1186/s12885-018-4033-229382323
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves gardasil 9 for prevention of certain cancers caused by five additional types of HPV. Available From: https://www.esmo.org/oncology-news/archive/fda-approves-gardasil-9-for-prevention-of-certain-cancers-caused-by-five-additional-types-of-hpv. Accessed September 8, 2021.
   Google Scholar
• JouraEA, AultKA, BoschFX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997–2008. doi:10.1158/1055-9965.epi-14-041025274978
   PubMed Web of Science ®Google Scholar
• SpinnerC, DingL, BernsteinDI, et al. Human papillomavirus vaccine effectiveness and herd protection in young women. Pediatrics. 2019;143(2):e20181902. doi:10.1542/peds.2018-190230670582
   PubMed Web of Science ®Google Scholar
• SafaeianM, RodriguezAC. Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol. 2014;180(11):1076–1081. doi:10.1093/aje/kwu26525355444
   PubMed Web of Science ®Google Scholar
• CornallAM, PhillipsS, CumminsE, GarlandSM, TabriziSN. In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for post-vaccine surveillance studies. J Virol Methods. 2015;214:10–14. doi:10.1016/j.jviromet.2014.12.00725528202
   PubMed Web of Science ®Google Scholar
• StanleyM, LowyDR, FrazerI. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24 Suppl 3:S3/106–13.
   PubMed Web of Science ®Google Scholar
• Istituto Superiore di Sanità. Available from: https://www.epicentro.iss.it/hpv/epidemiologia-cervicocarcinoma-italia. Accessed 98, 2021.
   Google Scholar
• Istituto Superiore di Sanità. Available from: https://www.epicentro.iss.it/vaccini/dati_Ita#hpv. Accessed 98, 2021.
   Google Scholar
• Giorgi RossiP, CarozziF, FedericiA, RoncoG, ZappaM, FranceschiS. Italian screening in HPV vaccinated girls consensus conference group. Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference. Prev Med. 2017;98:21–30. doi:10.1016/j.ypmed.2016.11.02027894910
   PubMed Web of Science ®Google Scholar
• PerkinsRB, GuidoRS, CastlePE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102–131. doi:10.1097/LGT.000000000000052532243307
   PubMed Web of Science ®Google Scholar
• Gazzetta Ufficiale. Available from: https://www.gazzettaufficiale.it/eli/gu/2012/03/26/72/sg/pdf. Accessed 98, 2021.
   Google Scholar
• RositchAF, SoetersHM, Offutt-PowellTN, WheelerBS, TaylorSM, SmithJS. The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecol Oncol. 2014;132:767–779. doi:10.1016/j.ygyno.2013.12.04024412508
   PubMed Web of Science ®Google Scholar
• IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC monographs on the evaluation of carcinogenic risks to humans. Ingested nitrate and nitrite, and cyanobacterial peptide toxins. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.
   Google Scholar
• PerezS, IñarreaA, Pérez-TanoiraR, et al. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain. Virol J. 2017;14:214. doi:10.1186/s12985-017-0879-129110680
   PubMed Web of Science ®Google Scholar
• GiannellaL, Delli CarpiniG, Di GiuseppeJ, PrandiS, TsiroglouD, CiavattiniA. Age-related changes in the fraction of cervical intraepithelial neoplasia grade 3 related to HPV genotypes included in the nonavalent vaccine. J Oncol. 2019;2019:7137891. doi:10.1155/2019/713789131781217
   PubMed Web of Science ®Google Scholar
• BarbieriD, NoceraM, GallinellaG, et al. Comparison of HPV sign genotyping test with INNO-LiPA HPV genotyping extra assay on histologic and cytologic cervical specimens. Diagn Microbiol Infect Dis. 2012;74(1):43–48. doi:10.1016/j.diagmicrobio.2012.05.01422717156
   PubMed Web of Science ®Google Scholar
• PichonM, Lebail-CarvalK, BillaudG, LinaB, GaucherandP, MekkiY. Decontamination of intravaginal probes infected by human papillomavirus (HPV) using UV-C decontamination system. J Clin Med. 2019;8:1776. doi:10.3390/jcm8111776
   Web of Science ®Google Scholar
• SpinilloA, DominoniM, BoschiAC, et al. Clinical significance of the interaction between human papillomavirus (HPV) type 16 and other high-risk human papillomaviruses in women with cervical intraepithelial neoplasia (CIN) and invasive cervical cancer. J Oncol. 2020;26:6508180.
   Google Scholar
• ArmitageP. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11(3):375–386. doi:10.2307/3001775
   Web of Science ®Google Scholar
• CovertC, DingL, BrownD, FrancoEL, BernsteinDI, KahnJA. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. Hum Vaccin Immunother. 2019;15(7–8):1962–1969. doi:10.1080/21645515.2018.156443830633598
   PubMed Web of Science ®Google Scholar
• McClungNM, GarganoJW, BennettNM, et al. Trends in human papillomavirus vaccine types 16 and 18 in cervical precancers, 2008–2014. Cancer Epidemiol Biomarkers Prev. 2019;28(3):602–609. doi:10.1158/1055-9965.EPI-18-088530792242
   PubMed Web of Science ®Google Scholar
• CornallAM, SavilleM, PymanJ; VACCINE Study Group. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination. Vaccine. 2020;38(40):6304–6311. doi:10.1016/j.vaccine.2020.07.03732736938
   PubMed Web of Science ®Google Scholar
• ReichO, RegauerS, KashoferK. Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study. Gynecol Oncol. 2020;158(1):112–116. doi:10.1016/j.ygyno.2020.04.68532354471
   PubMed Web of Science ®Google Scholar
• BrunoMT, ScaliaG, CassaroN, BoemiS. Multiple HPV 16 infection with two strains: a possible marker of neoplastic progression. BMC Cancer. 2020;20(1):444. doi:10.1186/s12885-020-06946-732429930
   PubMed Web of Science ®Google Scholar
• LeeSA, KangD, SeoSS, et al. Multiple HPV infection in cervical cancer screened by HPVDNAChip. Cancer Lett. 2003;198:187–192. doi:10.1016/s0304-3835(03)00312-412957357
   PubMed Web of Science ®Google Scholar
• GoodmanMT, McDuffieK, HernandezBY, et al. The influence of multiple human papillomavirus types on the risk of genotype-concordant incident infections of the anus and cervix: the Hawaii HPV cohort study. J Infect Dis. 2011;203:335–340. doi:10.1093/infdis/jiq05821208924
   PubMed Web of Science ®Google Scholar
• LandyR, WindridgeP, GillmanMS, SasieniPD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer. 2018;142:709–718. doi:10.1002/ijc.3109429023748
   PubMed Web of Science ®Google Scholar
• GuanP, Howell-JonesR, LiN, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–2359. doi:10.1002/ijc.2748522323075
   PubMed Web of Science ®Google Scholar
• CastlePE, KinneyWK, XueX, et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study. Ann Intern Med. 2018;168(1):20–29. doi:10.7326/M17-160929181509
   PubMed Web of Science ®Google Scholar
• CarozziFM, TorneselloML, BurroniE, et al.; HPV Prevalence Italian Working Group. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2389–2400. doi:10.1158/1055-9965.EPI-10-013120826836
   PubMed Web of Science ®Google Scholar
• GiannellaL, Giorgi RossiP, Delli CarpiniG, et al. Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3. Gynecol Oncol. 2021;161(3):741–747. doi:10.1016/j.ygyno.2021.03.02533795132
   PubMed Web of Science ®Google Scholar
• GiannellaL, BeraldiR, GiuliniS, CeramiLB, MfutaK, FacchinettiF. Nitric oxide metabolite levels and assessment of cervical length in the prediction of preterm delivery among women undergoing symptomatic preterm labor. Int J Gynaecol Obstet. 2012;116(3):223–227. doi:10.1016/j.ijgo.2011.10.02022196996
   PubMed Web of Science ®Google Scholar
• KyrgiouM, AthanasiouA, KallialaIEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017;11:CD012847.29095502
   PubMed Web of Science ®Google Scholar
• DallaPP, GiorgiRP, CollinaG, RoncoG; NTCC Pathology Group. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol. 2009;132(1):125–132. doi:10.1309/AJCPBRK7D1YIUWFP19864243
   PubMed Web of Science ®Google Scholar